US 12,421,251 B2
Cystic fibrosis transmembrane conductance regulator modulating agents
Alexander Russell Abela, Escondido, CA (US); Sunny Abraham, San Diego, CA (US); Corey Don Anderson, Brighton, MA (US); Vijayalaksmi Arumugam, San Marcos, CA (US); Jaclyn Chau, San Diego, CA (US); Jeremy Clemens, San Diego, CA (US); Thomas Cleveland, San Marcos, CA (US); Timothy A Dwight, Quincy, MA (US); Bryan A. Frieman, La Jolla, CA (US); Peter Grootenhuis, Del Mar, CA (US); Sara Sabina Hadida Ruah, La Jolla, CA (US); Yoshihiro Ishihara, San Diego, CA (US); Paul Krenitsky, San Francisco, CA (US); Jason McCartney, Cardiff by the Sea, CA (US); Vito Melillo, Escondido, CA (US); Mark Thomas Miller, Rancho Santa Fe, CA (US); Alina Silina, Needham, MA (US); Johnny Uy, San Diego, CA (US); and Jinglan Zhou, San Diego, CA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Appl. No. 17/600,829
Filed by VERTEX PHARMACEUTICALS INCORPORATED, Boston, MA (US)
PCT Filed Apr. 2, 2020, PCT No. PCT/US2020/026331
§ 371(c)(1), (2) Date Oct. 1, 2021,
PCT Pub. No. WO2020/206080, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/828,699, filed on Apr. 3, 2019.
Prior Publication US 2022/0372047 A1, Nov. 24, 2022
Int. Cl. C07D 515/08 (2006.01); C07D 215/233 (2006.01); C07D 239/69 (2006.01); C07D 405/12 (2006.01)
CPC C07D 515/08 (2013.01) [C07D 215/233 (2013.01); C07D 239/69 (2013.01); C07D 405/12 (2013.01); C07B 2200/05 (2013.01)] 25 Claims
 
1. A compound selected from Compound I:

OG Complex Work Unit Chemistry
a deuterated derivative of Compound I, and a pharmaceutically acceptable salt thereof.